Stem cell transplant is a promising treatment option for patients with myelodysplastic syndrome (MDS). Still, the decision to ...

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder ...

Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease. Treating a patient ...

At a median follow-up of 18 months, the OS rate was 95% and the DFS rate was 88%. 14 Long-term follow-up at a median of 53 ...